公司简介
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr...
关联新闻
- Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
- EU panel backs AstraZeneca hypertension drug baxdrostat
EU panel backs AstraZeneca hypertension drug baxdrostat
- AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
- AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
- FTSE 100 set for monthly gains; AstraZeneca up after results
London's FTSE 100 looked on track to log its first monthly gain in three months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.
- AstraZeneca Readies New Portfolio of Targeted Cancer Therapies
AstraZeneca is readying to file the first of a new portfolio of targeted cancer drugs for regulatory approval, moving to cement its position in one of the fastest-growing corners of the oncology marke...
- AstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment for adults with immunoglobulin A nephropathy, a rare kidney disease that can lead to ...
- Oracle stock's next big AI opportunity may have nothing to do with data centres
Oracle announced a healthcare artificial intelligence collaboration with AstraZeneca on Tuesday, expanding its ambitions beyond data centres as investors scrutinise the cost of its cloud infrastructur...